Verus Capital Partners’s Medifast MED Stock Holding History

Verus Capital Partners’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,177	Closed	-$216K	–	302
2022 Q2	$216K	Hold	1,177	–	–	0.04%	262
2022 Q1	$214K	Buy	+1,177	New	+$222K	0.03%	292
2020 Q1	$33K	Sell	525 -493	-48%	-$44.9K	0.01%	622
2019 Q4	$112K	Buy	+1,018	New	+$98.5K	0.04%	347

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Verus Capital Partners's MED Position: Q3 2022 in Review

Verus Capital Partners sold out of Medifast (MED) in Q3 2022, closing a stake of 1,177 shares — an estimated $216K sold.

Verus Capital Partners first reported a position in MED in Q4 2019 and held it in 4 quarters. The position peaked at $216K in Q2 2022. 263 funds tracked by Wall St. Rank hold MED as of Q3 2022.

Verus Capital Partners reported no remaining Medifast position as of Q3 2022 after selling out during the quarter.
Verus Capital Partners sold 1,177 Medifast shares in Q3 2022, an estimated $216K.
Verus Capital Partners first reported a position in Medifast in Q4 2019 and held it in 4 quarters.
Verus Capital Partners's Medifast position peaked at $216K in Q2 2022.
263 funds tracked by Wall St. Rank held Medifast as of Q3 2022.

Based on Verus Capital Partners's 13F filing for Q3 2022, filed 15 Nov 2022.